DaVita assumed with an Outperform at William Blair. William Blair analyst Matt Larew assumed coverage of DaVita from Margaret Kaczor and keeps an Outperform rating on the shares. The company’s renewed focus on execution within the kidney care business will provide more predictable results in the United States, while the international business should become profitable in 2018 and beyond, Larew tells investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.